__________________________________________________________________________________________ Molecular
Partners
DARPin therapeutics
“ DARPins were discovered and developed by our founders while at the University of Zurich , and from this discovery we have pioneered a new class of therapeutics with potential to treat a wide range of diseases . Today we are the global leader of DARPin therapeutics . With vast libraries of over one trillion potential DARPins , each of which can bind their own biologic target and be rationally and rapidly combined and screened , we are constantly working to expand our technical capabilities and further unlock the potential of DARPins to create novel therapeutics for patients .
“ There is great need to deliver diseasespecific solutions for diverse conditions . As our understanding of the mechanisms of various diseases deepens , the opportunity for DARPin therapeutics is greater than ever . To innovate and stay ahead of the curve , we are active on several fronts . We have built a clinical team and we partner with leading investigators and specialized centers to ensure optimal clinical development with the objective to
have early clinical readouts in relevant patient populations .”
As Molecular Partners marks 20 years of DARPin leadership and innovation in 2024 , the pursuit , consolidation , and meaningful use of knowledge remains central to the company ’ s mission . Moving into the future , Molecular Partners has added cutting-edge AI tools to its DARPin generation process . “ While we at Molecular Partners are building a therapeutics company leveraging DARPins and their unique advantages , we acknowledge that DARPins are a class of drugs , just like antibodies or small molecules , and we can ’ t do everything on our own . Accordingly , a long-term goal will be for universities and pharma companies , and everyone in between , to feel that this is a modality they should explore and leverage . There is so much more than can be done , and we want to facilitate learning wherever possible ,” Alex concludes . ■
www . molecularpartners . com
manufacturing-today . com 41